Newborns can't see clearly at birth. In fact, vision is about 20/400, making the first days of sight very blurry, like a camera out of focus. But within a week, a baby can focus on objects about 8 to 12 inches from his face.
(Wellâ¦sort of ânew.â) Tresiba is a long-acting insulin (like Lantus or Levemir) made by NovoNordisk. Itâs been available in Europe for several years now and is still awaiting FDA approval in the USA. (UPDATE: Tresiba is now approved by the FDA for use in the USA!)
Novo Nordisk launches Tresiba (insulin degludec) in United Kingdom and Denmark. TAGS. In March 2013, Novo Nordisk launched Tresiba (insulin degludec), its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be priced roughly 70% higher than the other leading basal insulins, Lantus (insulin glargine) and Levemir (insulin detemir), in the UK and about 49% higher than Lantus in Denmark.